- Protein Name
- Ephrin type-A receptor 4
- Gene Name
- Epha4
- Organism
-
Mus musculus
- Function
- Receptor tyrosine kinase which binds membrane-bound ephrin family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Highly promiscuous, it has the unique property among Eph receptors to bind and to be physiologically activated by both GPI-anchored ephrin-A and transmembrane ephrin-B ligands including EFNA1 and EFNB3. Upon activation by ephrin ligands, modulates cell morphology and integrin-dependent cell adhesion through regulation of the Rac, Rap and Rho GTPases activity. Plays an important role in the development of the nervous system controlling different steps of axonal guidance including the establishment of the corticospinal projections. May also control the segregation of motor and sensory axons during neuromuscular circuit development. In addition to its role in axonal guidance plays a role in synaptic plasticity. Activated by EFNA1 phosphorylates CDK5 at 'Tyr-15' which in turn phosphorylates NGEF regulating RHOA and dendritic spine morphogenesis. In the nervous system, plays also a role in repair after injury preventing axonal regeneration and in angiogenesis playing a role in central nervous system vascular formation. Additionally, its promiscuity makes it available to participate in a variety of cell-cell signaling regulating for instance the development of the thymic epithelium.
| Site |
Maximum Consensus Site Population |
Minimum Consensus Site Population |
Median Consensus Site Population |
| MPP |
17 |
4 |
7.0 |
| AAS |
16 |
5 |
11.0 |
| ATP |
21 |
1 |
16.0 |
| DFG |
18 |
10 |
14.0 |
| CMP |
3 |
3 |
3.0 |
| EDI |
13 |
9 |
11.0 |
| DRS |
26 |
23 |
24.5 |
| PDB ID |
Maximum Consensus Site Population |
| MPP site |
AAS site |
MT3 site |
LBP site |
ATP site |
DEF site |
DFG site |
CMP site |
PMP site |
EDI site |
DRS site |
PDIG site |
PIF site |
| Total Druggable Structures per Site |
1 |
1 |
0 |
0 |
3 |
0 |
1 |
0 |
0 |
0 |
4 |
0 |
0 |
|
2HEL
|
17 |
16 |
0 |
0 |
15 |
0 |
10 |
0 |
0 |
0 |
24 |
0 |
0 |
|
2XYU
|
0 |
0 |
0 |
0 |
19 |
0 |
0 |
3 |
0 |
0 |
26 |
0 |
0 |
|
2Y6M
|
0 |
5 |
0 |
0 |
16 |
0 |
0 |
0 |
0 |
9 |
23 |
0 |
0 |
|
AFQ03137
|
0 |
0 |
0 |
0 |
0 |
0 |
18 |
0 |
0 |
0 |
0 |
0 |
0 |
|
2Y6O
|
9 |
11 |
0 |
0 |
21 |
0 |
0 |
0 |
0 |
13 |
25 |
0 |
0 |